{"name":"Cephalon, Inc.","slug":"cephalon-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2811057000,"revenueGrowth":28.2,"grossMargin":0,"rdSpend":0,"netIncome":425745000,"cash":4891833000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2010"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Free doxorubicin hydrochloride","genericName":"Free doxorubicin hydrochloride","slug":"free-doxorubicin-hydrochloride","indication":"Breast cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Liposomal doxorubicin hydrochloride","genericName":"Liposomal doxorubicin hydrochloride","slug":"liposomal-doxorubicin-hydrochloride","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Free doxorubicin hydrochloride","genericName":"Free doxorubicin hydrochloride","slug":"free-doxorubicin-hydrochloride","phase":"phase_2","mechanism":"Doxorubicin hydrochloride intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death.","indications":["Breast cancer","Ovarian cancer","Lung cancer","Leukemia","Lymphoma"],"catalyst":""},{"name":"Liposomal doxorubicin hydrochloride","genericName":"Liposomal doxorubicin hydrochloride","slug":"liposomal-doxorubicin-hydrochloride","phase":"marketed","mechanism":"DNA and topoisomerase II","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNQVZ4Q1ItT3JQbmNlTXduRzZJQjg0VEptcTRPRXRhUzEzaTNkbjdaNnVzRl93MTVzNlc1eTdQNndOYkhWMWlqb2duZS04c2dzYlV5a2dZWk5IZVFOVU83RG5WMVhkZEdnX19IN3UxTkFYZVdkVzFTdzgzQXhoQlhHSHIzbDdQOVdUdVNsdGZUYWF0NXJwX2xQNFptVzZfY2M?oc=5","date":"2026-02-08","type":"regulatory","source":"lupin.com","summary":"Lupin Receives FDA Approval for Generic Nuvigil® Tablets - Lupin | Press Release - lupin.com","headline":"Lupin Receives FDA Approval for Generic Nuvigil® Tablets - Lupin | Press Release","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQbFlZSTVOMmxWN19GZWtGSlRQZHVMMVJuUGVHemI1M25mUldpWTZOLVZ2VGU4RnZDRVNwZ2toR0ZSbnktUGJRWVdrYW1qNzNmazAzZHBHR3VmdTU5d3hLX29DcVFhbnFuSkNhc1pNMlRwbnpqRGZXaHBOVkZYdVY3aW5NaG91azZNU21qMVZ6WWxQZnAxTVA3VTdsWFTSAVZBVV95cUxOcHpRT245WDZZZWpQaW5GMHhhcWpfYnpGM2FpNGlpdDAzZnJqUzYtYXhKS29XMnlZZUdKdXFCVHpmVG1vQzdDSVg1cTl3MERndjZGQnR4QQ?oc=5","date":"2025-10-23","type":"pipeline","source":"Law360","summary":"Teva, Cephalon Can't Upend €60M Fine In Pay-For-Delay Case - Law360","headline":"Teva, Cephalon Can't Upend €60M Fine In Pay-For-Delay Case - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQSUJWb29wdy1fc3JYaGd4T0ZsYW80ZHl2bEZBNk1qSHQzUTByLXdVTG9rdl9xaDNFdEI2dzNIZm9Cai0zd0hYalN5aGdQaFlxbUtyRUR5SThxd3l6VVc4YmNFU09UekF5THk3R2tZb01mRWNNcENDdXBHYm5rQXU5UTZTR3F2cEpWNHhQYnhhSFJhNVI2MzJGcWptTUg?oc=5","date":"2024-04-30","type":"pipeline","source":"Bloomberg Law News","summary":"Teva Beats $200 Million Lawsuit Over Pharmaceutical Acquisition - Bloomberg Law News","headline":"Teva Beats $200 Million Lawsuit Over Pharmaceutical Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPU0pDd0xHLU51Njh2NjVzVVA3aGJHeVdVTm5seWtUVEtXUlkzYy11YUt1UE1sdUExaExfY1phdVdDRG5jZVZyelA0TGxkTTdKclRYT05qS3R3QXpYajhtOHV2SzdOdWY5cXFabVZaN2ZKb0hTLWNBcUEtV1BTWkNvUnBleGI2a2FKQV9yOGhaNzBjRlFVbnJHdUV5M2ZmTWRlNy1kSFkwNWozMXdyYjJaSUxjV3pFRFlhemUzTDZxQ0tRRTlBa0VDLUc2WlgxX3d4VC1kVU94SzA3SmNXRFRkTlhicFh6eEVFX2Q5aVMtWUZSOHdfY1Vj?oc=5","date":"2023-10-18","type":"pipeline","source":"Cleary Antitrust Watch","summary":"Teva And Cephalon v. Commission (Case T-74/21): The General Court Continues To Uphold Pay-For-Delay Infringement Decisions - Cleary Antitrust Watch","headline":"Teva And Cephalon v. Commission (Case T-74/21): The General Court Continues To Uphold Pay-For-Delay Infringement Decisio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9FR1NlSmJrc0R4Zzl6ZmpEcVdCOWpldlFKb2kxOVBkdUtPNTlYYjVZcHJYRTYxV3l3aFROaVl3LU1vVHR0WnpzN0RnN05DaUFQVWJ6eDllR2kxWXc?oc=5","date":"2023-07-28","type":"pipeline","source":"EurekAlert!","summary":"Michael Bayewitch, PhD named Head of BD and Licensing North America for Insilico Medicine - EurekAlert!","headline":"Michael Bayewitch, PhD named Head of BD and Licensing North America for Insilico Medicine - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPY1RxTFQ1V1E5Z2Zob1BTanFQTjhudWFhRXpKbkdNeXREbGtxTXNRR05wbUdUT01nNFltZWN0bG12dlZiMGhKNXFOa1Z4Q3JlRFM4cmZ6RndxeTVOMHN0eFE0X05Yc2VmVE1fbUFhb1NBbndmWGNKbC15RF9xd09XVkhpTTZlUWx2WUlfdEdPY2h3SnBHcWRWWmE2QjlqMXFxZnRwNldFNF8wUdIBrwFBVV95cUxPcUlCT2Y3TFJ3LWdNdGdNN0V6LTFLc3pKV3JvRkdRbnZ2ejUxd2xBNHRVZlZXMU9aSTQyTnlOX3JSdVk0VEE4RUhjS1A3U29VU1lvR0Z6aXVfX04zYld1Y1NtVGE5ODIxVjNwRnhydkhrVFROVjZjM2paM3kycWI5c2JoZ2NwekNBd0dBOW1Cb09OUEJfdllEaVk2eHM4dThrU2s3VFJiMHp6QkZSTWo4?oc=5","date":"2019-06-28","type":"pipeline","source":"CBS News","summary":"Lollipop made with powerful opioid fentanyl was illegally marketed, ex-pharma rep says - CBS News","headline":"Lollipop made with powerful opioid fentanyl was illegally marketed, ex-pharma rep says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOWGtidWlJaVhfN3gyVTg0eVVTbUFYOE4wTF9HVHJMSEROcGxhbTl1Z3pTWEFIQWw2cHRWMm95dG1xenl6Rk8xdVBaX1JsaDI4VEZET2EySmtvNWRLTjlDRVpJRXJIWHR5VkZSSmRKSHFXbFBpdi1KWklnOU56YTh3ODlHc28?oc=5","date":"2017-07-17","type":"pipeline","source":"Financial Times","summary":"EU accuses Teva Pharmaceutical of anti-competitive behaviour - Financial Times","headline":"EU accuses Teva Pharmaceutical of anti-competitive behaviour","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOX0dTRVJLVEpFeVVDZkdENnpmOGFXb3pTaFJ3V2xIbGUtYTJjd0lpdWVESEpodjRVclJJSUxPZWhKU1g5MUVBOFpiRHZQQWdaV0VtbXVhM0JJbm9ScGtHMG1ialp6RmY4WHJ1c3N3ZXEzYnMySEJOcW9Zelp1NmFVV1VWWHhJbDBEYnhxVF8xUEJxeDZuZDFzc1BQU3pWQk1XeXZ3WmRYczdKa1U1QmFVaGRBSEN0cHk0WEx3TEg3OVZuNU9ESVl0UzJ1OTZ5NkNTdGRtQ3p3eGM0UQ?oc=5","date":"2015-06-18","type":"pipeline","source":"orrick.com","summary":"Cephalon and Teva's $1.2 Billion Consent Order with the FTC: Is it Really a Harbinger of Things to Come? - orrick.com","headline":"Cephalon and Teva's $1.2 Billion Consent Order with the FTC: Is it Really a Harbinger of Things to Come?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNSDkzYmg2QXI1bnBjc3lDY0tsUEVzR0ZWTFNpeDVnMmFjZXY0amo2SEsyY1NYNHRqbWZFSUNsQ2lKOXJXVEdfMVMxTmUtSjhKcFlRT0Q3V2J2NWZuZE9tbnp0R0JXNDVaT29RdTU0V1NRRWlNdW1qai1HelBCdlJoWDdxNW1zTlVBRU1aMzg0RQ?oc=5","date":"2015-05-28","type":"patent","source":"The New York Times","summary":"Teva Settles Cephalon Generics Case With F.T.C. for $1.2 Billion (Published 2015) - The New York Times","headline":"Teva Settles Cephalon Generics Case With F.T.C. for $1.2 Billion (Published 2015)","sentiment":"neutral"},{"date":"2015-03-27","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdWpPVW5OME1ocVdTZ2QtTGpKdmZiVTk4WTNac2s5YjZ3bnhmd1MyOVRFTVBLQzB1RmZESlJoN1JSdUo1Y3JITmxtRHhMWUhXTzZGZU93UHdjVHZrNno3WEMtcHcwZHVia2ZnamRCTUdQYW1qbXdiWWszcVdLNV9sR00yRDVXdkJC?oc=5","date":"2014-06-24","type":"pipeline","source":"WHYY","summary":"How I survived the topsy-turvy pharmaceutical industry - WHYY","headline":"How I survived the topsy-turvy pharmaceutical industry","sentiment":"neutral"},{"date":"2011-11-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SC 13D","headline":"SC 13D Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5Ca3g4SzNNMEI5OFMtWWEzTGEwT2dKUGJzczRFdFhlR0pWcloxc3RIeGFGbkd5RW9KczlEcjE5VVAzWEVna0otZ1ZPbVI1Sl81NF9IYVdQWWZFaE5wbGlyaGEwNzZ5dmZrT1R4eFA1LTU3ODRsU250eGFlaHJYdw?oc=5","date":"2011-05-02","type":"deal","source":"CBC","summary":"Teva buys Cephalon for $6.8B US - CBC","headline":"Teva buys Cephalon for $6.8B US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPeWhvQk5tRnNKTi1xaGhpYW9ldlNnME1VMVZrV3hRZ0V5d1ZPSHItSG8wMlpyOUlQbllYLUVBX2tQTmkxLTBuMVBQeUhwdmphRDlJRUZfNk5BejdCaGR0cVp6M01fRV9fYXloU3VmN2IxWmlLUUtKR3Vidk8tUVdNYjJQRllPS3FqRmYycGFRWXF6enR2ZjlWRVJDU0h3RElBalhZRFBabnJOd0MyU3ZCZ2NLN3NYMVdQdHFxb2RPQjVXQQ?oc=5","date":"2008-11-25","type":"pipeline","source":"Fierce Biotech","summary":"Cephalon and ImmuPharma Sign a $15 Million Option Agreement for Late- Stage Experimental Lupus Medication - Fierce Biotech","headline":"Cephalon and ImmuPharma Sign a $15 Million Option Agreement for Late- Stage Experimental Lupus Medication","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2811057000,"revenuePeriod":"2010-12-31","revenueHistory":[{"value":2811057000,"period":"2010-12-31"},{"value":2192308000,"period":"2009-12-31"},{"value":1974554000,"period":"2008-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":425745000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":4891833000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}